Group 1 - The A-share silicon-based materials sector experienced a pullback during trading, with significant declines in several companies [1] - Hongbai New Materials hit the daily limit down, indicating a strong negative market reaction [1] - Other companies such as Feilu Co., Jitai Co., Chenguang New Materials, and Jihua Group also saw declines, following the trend set by Hongbai New Materials [1]

[Current Period Performance Forecast Details](index=1&type=section&id=Item%201.%20Current%20Period%20Performance%20Forecast) The company anticipates a significant 95.60% year-over-year decrease in net profit attributable to shareholders for H1 2025 to 4.4 million yuan, while net profit attributable to shareholders excluding non-recurring gains/losses is expected to narrow its loss to -9.8 million yuan, a 24.71% year-over-year improvement; this forecast is unaudited Key Performance Indicators Forecast | Indicator | 2025 H1 Forecast | 2024 H1 | YoY Change | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | 4.40 million yuan | 100.07 million yuan | -95.60% | | Net Profit Attributable to Parent Company Shareholders Excluding Non-Recurring Gains/Losses | -9.80 million yuan | -13.02 million yuan | +24.71% | - The performance forecast data has not been audited by a certified public accountant[4](index=4&type=chunk) [Prior Period Performance Review](index=1&type=section&id=Item%202.%20Prior%20Period%20Operating%20Performance%20and%20Financial%20Position) In the same period of 2024, the company achieved a net profit attributable to parent company shareholders of 100.07 million yuan, but a net loss attributable to parent company shareholders excluding non-recurring gains/losses of 13.02 million yuan, indicating that prior period profit was primarily driven by non-recurring items 2024 H1 Key Financial Data | Indicator | 2024 H1 Data | | :--- | :--- | | Total Profit | 141.07 million yuan | | Net Profit Attributable to Parent Company Shareholders | 100.07 million yuan | | Net Profit Attributable to Parent Company Shareholders Excluding Non-Recurring Gains/Losses | -13.02 million yuan | | Earnings Per Share | 0.14 yuan | [Analysis of Performance Change](index=2&type=section&id=Item%203.%20Primary%20Reasons%20for%20Current%20Period%20Performance%20Decline) The significant decline in net profit attributable to parent company shareholders is primarily due to a 159.39 million yuan asset disposal gain in the prior period, leading to an 87.44% year-over-year decrease in current period net non-recurring gains/losses, which explains the improved non-recurring adjusted net profit despite the overall decline - Current period net non-recurring gains/losses are approximately **14.20 million yuan**, a significant **87.44% year-over-year decrease**[7](index=7&type=chunk) - The performance change is mainly due to a **159.39 million yuan** asset disposal gain recognized by the company's wholly-owned subsidiary in the prior period due to government demolition requirements, which did not recur in the current period[7](index=7&type=chunk) [Risk Warning](index=2&type=section&id=Item%204.%20Risk%20Warning) The company emphasizes that this performance forecast is unaudited and currently there are no other significant uncertainties affecting the accuracy of the forecast content - The company's estimated performance has not been audited by the annual certified public accountant, and the company confirms there are no significant uncertainties affecting the accuracy of this performance forecast[8](index=8&type=chunk) [Other Explanatory Notes](index=2&type=section&id=Item%205.%20Other%20Explanatory%20Notes) The company reminds investors that the disclosed data is preliminary, and the final accurate financial data will be based on the officially released 2025 semi-annual report; investors are advised to be aware of investment risks - The above forecast data is only preliminary, and the specific accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report[9](index=9&type=chunk)

Core Viewpoint - The price of H acid has significantly increased, leading dye companies to cautiously manage their production capacity [1] Company Summaries - Jinji Co. has not yet started trial production of its 8000 tons capacity for H acid [1] - Runtou Co. and Jihua Group have their H acid facilities currently in a state of suspension [1] - Zhejiang Longsheng has some facilities in trial production [1] Industry Insights - Recent data indicates that H acid prices have surpassed 44,000 yuan per ton, reflecting an increase of 8,000 yuan per ton since the beginning of the year [1]

证券代码：603980 证券简称：吉华集团 公告编号：2025-046 风险提示：公司购买的"中建投信托·安泉593号（青岛融创）集合 资金信托计划"存在延期兑付风险。鉴于此次投资款项的收回尚存在不确 定性，并基于非保本理财产品的性质，故存在本金无法全额收回的风险。 一、信托延期兑付情况： （一）信托计划名称：中建投信托·安泉593号（青岛融创）集合资金 信托计划 关于中建投信托产品逾期兑付事项进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 信托产品名称：中建投信托·安泉593号（青岛融创）集合资金信托 计划（以下简称"本信托计划"） 受托方：中建投信托股份有限公司（以下简称"中建投信托"） 购买金额：5,000万元（公司自有资金） 浙江吉华集团股份有限公司 （四）清算期限：2023年2月9日起，至信托财产全部变现并完成向受 益人分配之日止 公司将继续积极联系各相关方，尽最大努力保障公司利益。督促中建投信 托密切追踪融资人及项目情况，尽快向公司兑付余下的投资本息。 （二）理财金额：5,000万元 ...

吉华集团：累计收到中建投信托产品本金2561.48万元 智通财经6月23日电，吉华集团(603980.SH)公告称，公司购买的"中建投信托·安泉593号（青岛融创）集 合资金信托计划"存在延期兑付风险。公司于2025年6月23日收到本金1748.00万元，累计收到本金 2561.48万元，收益306.25万元。公司将继续积极联系各相关方，督促中建投信托尽快向公司兑付余下的 投资本息。 ...

Group 1: REITs Market Overview - The REITs index continues to rise, with property types showing strength this week, indicating a recovery in market activity [2][3] - As of June 13, 2025, the total market value of REITs reached 204.08 billion yuan, an increase of 2.01 billion yuan from the previous week [3][4] - The average weekly increase for property-type REITs was 0.95%, outperforming other categories [4] Group 2: H Acid Market Dynamics - The average market price of H acid as of June 13, 2025, was 41,750 yuan per ton, up 5,750 yuan per ton since early January 2025 [6][7] - Supply-demand tightness is expected to push H acid prices higher, with effective domestic production capacity currently below 60,000 tons, leading to a supply gap of over 10% [8][9] - Companies with integrated production capacity for H acid and reactive dyes, such as Zhejiang Longsheng and Jinchicken Co., are expected to benefit from rising prices [9][10] Group 3: North Exchange Market Insights - As of June 13, 2025, the North Exchange A-share component stocks totaled 267, with an average market capitalization of 3.046 billion yuan [11] - The North Exchange 50 index experienced a decline of 3.11%, while the average daily trading volume increased by 31.28% compared to the previous week [11][12] - The newly listed company, Jiao Da Tie Fa, focuses on intelligent products and services for rail transit, with projected revenue of 335 million yuan for 2024 [12] Group 4: AI Chip Design System Launch - The world's first AI-based chip design system, "Enlightenment," was launched, achieving full automation in chip design processes [14][16] - The system can design a 32-bit RISC-V CPU in just five hours, matching the performance of Intel 486, and has completed its first silicon [16] - This innovation is expected to significantly enhance the efficiency of chip design and development in the semiconductor industry [16] Group 5: New Materials Industry Outlook - The new materials sector is anticipated to enter a growth phase driven by increasing downstream demand and supportive policies [14][25] - Key areas of focus include semiconductor materials, renewable energy technologies, and biodegradable plastics, which are expected to see significant investment and development [19][23] - The industry maintains a "recommended" rating due to its potential for growth and innovation [25]

Investment Rating - The industry is rated as "Recommended" for investment, indicating a favorable outlook for the sector [2][8]. Core Insights - The price center of H acid is expected to rise due to tightening supply and demand dynamics, with a current market average price of 41,750 RMB/ton as of June 13, 2025, reflecting an increase of 5,750 RMB/ton since early January 2025 [6][8]. - The active dye industry is undergoing a phase of industrial upgrading and consolidation, with many small and medium enterprises being eliminated due to sustained price pressure since late 2019 [6][8]. - H acid, a key raw material for producing active dyes, constitutes 30%-50% of the total cost, and its price increase is likely to positively impact active dye prices, which have recently risen from 20 RMB/kg to 23 RMB/kg [6][8]. Summary by Sections Industry Overview - H acid production faces challenges such as high energy consumption and significant environmental pollution, leading to production halts in developed countries, with global capacity concentrated in China and India [6][8]. - Domestic effective H acid capacity is currently below 60,000 tons, resulting in a supply gap exceeding 10% [6][8]. Cost and Pricing Dynamics - The cost support from H acid is expected to facilitate a smoother transmission of price increases in active dyes, benefiting companies with integrated production capacities [6][8]. - The report highlights that companies like Zhejiang Longsheng, Jinchicken Co., Luntai Co., and Jihua Group are well-positioned to benefit from these dynamics [6][8]. Key Companies and Profit Forecast - Key companies to watch include: - Zhejiang Longsheng (Stock Code: 600352.SH) with an estimated EPS of 0.67 for 2025 and a PE ratio of 16 [9]. - Jinchicken Co. (Stock Code: 300798.SZ) currently un-rated but with significant production capacity [9]. - Luntai Co. (Stock Code: 002440.SZ) with an estimated EPS of 0.25 for 2025 and a PE ratio of 33 [9]. - Jihua Group (Stock Code: 603980.SH) with an estimated EPS of 0.25 for 2024 and a PE ratio of 81 [9].

Group 1 - The core viewpoint of the article highlights the active cash dividend distribution among listed companies, with a total of 3,676 companies proposing distribution plans for the 2024 fiscal year, and 3,671 of them including cash dividends totaling 1.64 trillion yuan [1][2] - The implementation of dividend distribution is concentrated around two key dates: the ex-dividend date and the record date, with 1,948 companies having already implemented their distribution plans [1] - Companies with significant cash dividends include Perlay, which offers 11.90 yuan per 10 shares, followed by Anji Food and Zhengqi Co., with 10.15 yuan and 9.20 yuan per 10 shares respectively [1][2] Group 2 - Among the companies distributing dividends today, Shanke Intelligent, Nanling Technology, and Junxin Co. have the highest stock transfer ratio of 4.00 shares for every 10 shares [2] - The stock performance of companies with dividend distributions shows that Yingli Automotive has the highest increase over the past five days, with a rise of 33.33%, followed by Deyi Culture and Hengbao Co. [2][3] - A detailed list of companies and their respective dividend distributions and stock performance is provided, indicating various payout amounts and recent price changes [3][4]

证券代码：603980 证券简称：吉华集团 公告编号：2025-045 浙江吉华集团股份有限公司 关于子公司获得《药品注册证书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，浙江吉华集团股份有限公司（以下简称"公司"）下属控股子 公司江苏康倍得药业股份有限公司（以下简称"康倍得"）同时收到国家 药品监督管理局核准签发的两项利斯的明透皮贴剂《药品注册证书》，现 将有关情况公告如下： 药品名称：利斯的明透皮贴剂 主要成分：利斯的明 剂型：贴剂 规格：4.6mg/24小时，9.5mg/24小时 注册分类：化药4类 证书编号：2025S01723，2025S01724 药品注册标准编号：YBH08312025 药品批准文号：国药准字H20254469，国药准字H20254470 药品批准文号有效期：至2030年06月09日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本 品符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明 书、标签及生产工艺照所附执行。 二、药品其他相关情况 一 ...

Core Viewpoint - Jihua Group's subsidiary Jiangsu Kangbeide Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for two registrations of Lisdexamfetamine transdermal patches, indicating a significant advancement in the company's product portfolio and potential market opportunities [1] Group 1 - The approved drug is Lisdexamfetamine transdermal patch, with active ingredient Lisdexamfetamine [1] - The specifications for the patches are 4.6mg/24 hours and 9.5mg/24 hours, classified as chemical drug category 4 [1] - The registration certificates have effective dates until June 9, 2030, with specific approval numbers provided [1] Group 2 - The total research and development investment for the Lisdexamfetamine transdermal patch project amounts to approximately 20 million RMB [1]